The "Medwell Calamities" ended quite well....Whether it was failure of their phase III as BioMS, or the "Recovery Room Scheme" that "palgued the play", or the "unexplained DE-LISTING" from the TSX that was announced on Sept.7th ( first day back from summer break ) and executed in February ( many months later ) In the end people owning Medwell ( including Birch Hill Equity) did VERY WELL and maintain the "softened shares of Spectral"
Toykyo you seem quite focussed on a financing, I would wait for the company to visit the FDA with their "ROBUST DATA" before "calling the financing"
I would also expect that the company will have to explain the interim data efficacy that led to the 29 CENT financing for Birch Hill, Toray and the 10M shares that went to "other investors"
Toykyo, do you know anything about Cormark, Sprott, or anything about 5 I research?
We seem to be garning much attention now that our shares are "suddenly on sale"
Thanks in advance, you seem rather intelligent
Sqr